Haemophilia Treatment – Current and Future Challenges

Late immune tolerance induction in an adult with severe haemophilia A and high‐responder inhibitor: 1‐year outcome

“…Three infectious events occurred: one gastroenteritis (sixth week) and two acute bronchitis (Phase-III). The patient's compliance, the clinical efficacy and the biological parameters (inhibitor titre, trough level) supported the decision of the healthcare providers to continue ITI with high doses of FVIII for at least 12 months [8] to stabilize the trough level at 6% and fulfil the criteria of successful ITI.…”